Dr. Ibach is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9957 Sherrill Blvd
Knoxville, TN 37932Phone+1 865-693-2255Fax+1 865-691-7888
Summary
- Dr. Daniel Ibach is an oncologist in Powell, TN and is affiliated with multiple hospitals in the area, including Blount Memorial Hospital, Fort Loudoun Medical Center, Fort Sanders Regional Medical Center, and Parkwest Medical Center. He received his medical degree from University of Tennessee Health Science Center College of Medicine and has been in practice 23 years. He is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 1998 - 2000
University of Tennessee College of Medicine at ChattanoogaResidency, Internal Medicine, 1995 - 1997
University of Tennessee Health Science Center College of MedicineClass of 1994
Certifications & Licensure
TN State Medical License 1995 - 2026
FL State Medical License 1998 - 2008- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Publications & Presentations
PubMed
- 1 citationsNeuroendocrine tumor chromogranin A response following synthetic somatostatin analog (lanreotide): Early observations from an isolated duodenal neoplasm .E Scott Sills, Samuel H Wood, Seang Lin Tan, Daniel M Ibach
Neuro Endocrinology Letters. 2023-07-05 - 1 citationsOvercoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone.Alexandra Erath, Dilan A Patel, Eric A Hosack, James E Patanella, Daniel M Ibach
World Journal of Oncology. 2020-02-01
Press Mentions
Top Docs 2024March 2nd, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
